Trial Profile

An Open-Label Safety Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen (ISIS 304801)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olezarsen (Primary)
Indications Hyperlipoproteinaemia type I
Focus Adverse reactions; Registrational
Sponsors Ionis Pharmaceuticals

Most Recent Events

04 Dec 2024 Planned End Date changed from 1 Jun 2025 to 1 Jun 2027.
04 Dec 2024 Planned primary completion date changed from 1 Mar 2025 to 1 Jun 2027.
02 Sep 2024 Interim Results assessing safety and pharmacokinetic of Transition of patients with familial chylomicronaemia syndrome from volanesorsen to olezarsen presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com